Evidence map›Paper›PMID 42366059›Full record

ArticleJournal of clinical and experimental hematopathology : JCEH2026

Histiocytic sarcoma with a common clonal origin emerged after 33 years from B-cell precursor acute lymphoblastic leukemia.

Misayo Miyake, Naoko Tsuyama, Yuki Togashi, Akito Dobashi, Yuri Okimoto, Hiroko Noguchi, Dai Maruyama, Kengo Takeuchi

Abstract readCase Reports
In one paragraph

Article in Journal of clinical and experimental hematopathology : JCEH, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Misayo MiyakeDivision of Pathology, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.
Naoko TsuyamaDivision of Pathology, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.
Yuki TogashiDivision of Pathology, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.
Akito DobashiDivision of Pathology, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.
Yuri OkimotoDivision of Hematology and Oncology, Chiba Children's Hospital, Chiba, Japan.
Hiroko NoguchiDepartment of Pathology, Kimitsu Chuo Hospital, Chiba, Japan.
Dai MaruyamaDepartment of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Kengo TakeuchiDivision of Pathology, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Histiocytic sarcoma (HS) is a rare, aggressive malignant neoplasm characterized by histiocytic features, frequently presenting in advanced clinical stages and associated with a poor prognosis. Although HS can occur sporadically or secondary to other hematological malignancies, cases with a long latency period have been rarely reported. This case report presents a unique case of secondary HS diagnosed 33 years and seven months after the initial diagnosis of B-cell precursor acute lymphoblastic leukemia. Both neoplasms shared identical immunoglobulin heavy chain and T-cell receptor gene rearrangements, confirming a clonal relationship. To the best of our knowledge, this case represents the longest reported interval between primary leukemia and secondary HS, highlighting the potential for lineage switching and transformation over extended periods. These findings underscore the need for ongoing research on the mechanisms underlying "transdifferentiation", including the roles of transcription factors, cytokine signaling, and epigenetic modifications.

Indexed as

Histiocytic SarcomaPrecursor B-Cell Lymphoblastic Leukemia-LymphomaHumansacute lymphoblastic leukemiahistiocytic sarcomatransdifferentiation

Identifiers

PMID42366059
PMCPMC13472141

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.